Diagnostic contribution of donor-specific antibody characteristics to uncover late silent antibody-mediated rejection results of a cross-sectional screening study

Transplantation

Volumn 101, Issue 3, 2017, Pages 631-641

  Eskandary, Farsad ^a,b   Bond, Gregor ^a   Kozakowski, Nicolas ^a   Regele, Heinz ^a   Marinova, Lena ^a   Wahrmann, Markus ^a   Kiki, Ẑeljko ^a   Haslacher, Helmuth ^a   Rasoul Rockenschaub, Susanne ^a   Kaltenecker, Christopher C ^a   König, Franz ^a   Hidalgo, Luis G ^b,c   Oberbauer, Rainer ^a   Halloran, Philip F ^b,c   Böhmig, Georg A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4D; DONOR SPECIFIC ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; ALLOANTIBODY; BIOLOGICAL MARKER; COMPLEMENT; HLA ANTIGEN; IMMUNOGLOBULIN G;

ADULT; ANTIBODY MEDIATED REJECTION; ANTIBODY SCREENING; ARTICLE; COHORT ANALYSIS; COMPLEMENT FIXATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; PREDICTIVE VALUE; PROSPECTIVE STUDY; ADVERSE EFFECTS; AREA UNDER THE CURVE; ASYMPTOMATIC DISEASE; BIOPSY; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPLEMENT FIXATION TEST; FLOW CYTOMETRY; GRAFT REJECTION; HISTOCOMPATIBILITY; IMMUNOLOGY; KIDNEY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PREVALENCE; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SEROLOGY; TREATMENT OUTCOME;

ADULT; AREA UNDER CURVE; ASYMPTOMATIC DISEASES; BIOMARKERS; BIOPSY; CHI-SQUARE DISTRIBUTION; COMPLEMENT FIXATION TESTS; COMPLEMENT SYSTEM PROTEINS; CROSS-SECTIONAL STUDIES; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN G; ISOANTIBODIES; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SEROLOGIC TESTS; TREATMENT OUTCOME;

EID: 84989214539     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001195     Document Type: Article

References (53)

1. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12:388-399.
2. Djamali A, Kaufman DB, Ellis TM, et al. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant. 2014;14:255-271.
3. Halloran PF, Chang J, Famulski K, et al. Disappearance of Tcell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients. J Am Soc Nephrol. 2014;26:1711-1720.
4. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14:272-283.
5. Tait BD, Hudson F, Cantwell L, et al. Reviewarticle: Luminex technology for HLA antibody detection in organ transplantation. Nephrology (Carlton). 2009;14:247-254.
6. Gebel HM, Bray RA. HLA antibody detection with solid phase assays: great expectations or expectations too great? Am J Transplant. 2014; 14:1964-1975.
7. Bartel G, Regele H, Wahrmann M, et al. Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on longterm allograft outcomes. Am J Transplant. 2008;8:2652-2660.
8. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157-1167.
9. Böhmig GA, Bartel G, Wahrmann M. Antibodies, isotypes and complement in allograft rejection. Curr Opin Organ Transplant. 2008;13:411-418.
10. Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol. 2011;72:849-858.
11. Wahrmann M, Exner M, Regele H, et al. Flow cytometry based detection of HLA alloantibodymediated classical complement activation. J Immunol Methods. 2003;275:149-160.
12. Bartel G,Wahrmann M, Schwaiger E, et al. Solid phase detection of C4dfixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients. Transpl Int. 2012;26:121-130.
13. Smith JD, Hamour IM, Banner NR, et al. C4d fixing, luminex binding antibodies-a new tool for prediction of graft failure after heart transplantation. Am J Transplant. 2007;7:2809-2815.
14. Visentin J, Vigata M, Daburon S, et al. Deciphering complement interference in anti-human leukocyte antigen antibody detection with flow beads assays. Transplantation. 2014;98:625-631.
15. Schwaiger E, Wahrmann M, Bond G, et al. Complement component C3 activation: the leading cause of the prozone phenomenon affecting HLA antibody detection on single-antigen beads. Transplantation. 2014;97: 1279-1285.
16. Bartel G,WahrmannM, Exner M, et al. In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Am J Transplant. 2008;8:41-49.
17. Yabu JM, Higgins JP, Chen G, et al. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation. 2011;91:342-347.
18. Sutherland SM, Chen G, Sequeira FA, et al. Complement-fixing donorspecific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant. 2012;16:12-17.
19. Freitas MC, Rebellato LM, Ozawa M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation. 2013;95:1113-1119.
20. Loupy A, Lefaucheur C, VernereyD, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl JMed. 2013;369:1215-1226.
21. Sicard A, Ducreux S, Rabeyrin M, et al. Detection of C3d-binding donorspecific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol. 2014;26:457-467.
22. Bartel G, Wahrmann M, Exner M, et al. Determinants of the complementfixing ability of recipient presensitization against HLA antigens. Transplantation. 2007;83:727-733.
23. Schaub S, Hönger G, Koller MT, et al. Determinants of C1q binding in the single antigen bead assay. Transplantation. 2014;98:387-393.
24. Tambur AR, Herrera ND, Haarberg KM, et al. Assessing antibody strength: comparison of MFI, C1q, and titer information. Am J Transplant. 2015;15: 2421-2430.
25. Schnaidt M, Weinstock C, Jurisic M, et al. HLA antibody specification using single-antigen beads-a technical solution for the prozone effect. Transplantation. 2011;92:510-515.
26. Eskandary F, Bond G, Schwaiger E, et al. Bortezomib in late antibodymediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial. Trials. 2014;15:107.
27. Rule AD, Larson TS, Bergstralh EJ, et al. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141:929-937.
28. Süsal C, Seidl C, Schönemann C, et al. Determination of unacceptable HLA antigen mismatches in kidney transplant recipients: recommendations of the German Society for Immunogenetics. Tissue Antigens. 2015; 86:317-323.
29. Wahrmann M, Bartel G, Exner M, et al. Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Transpl Int. 2009;22:982-989.
30. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128-138.
31. Mizutani K, Terasaki P, Hamdani E, et al. The importance of anti-HLAspecific antibody strength in monitoring kidney transplant patients. Am J Transplant. 2007;7:1027-1031.
32. YellM,Muth BL, Kaufman DB, et al. C1q binding activity of de novo donorspecific HLA antibodies in renal transplant recipients with and without antibody-mediated rejection. Transplantation. 2015;99:1151-1155.
33. Sapir-Pichhadze R, Curran SP, John R, et al. A systematic review of the role of C4d in the diagnosis of acute antibody-mediated rejection. Kidney Int. 2014;87:182-194.
34. Kikic Z, Kainz A, Kozakowski N, et al. Capillary C4d and kidney allograft outcome in relation to morphologic lesions suggestive of antibody-mediated rejection. Clin J Am Soc Nephrol. 2015;10:1435-1443.
35. Tambur AR, Haarberg KM, Friedewald JJ, et al. Unintended consequences of the New National Kidney Allocation Policy in the United States. Am J Transplant. 2015;15:2465-2469.
36. Lefaucheur C, Viglietti D, Bentlejewski C, et al. IgG donor-specific antihuman HLA antibody subclasses and kidney allograft antibody-mediated injury. J Am Soc Nephrol. 2015;27:293-304.
37. Murata K, Fox-Talbot K, Qian Z, et al. Synergistic deposition of C4d by complement-activating and non-activating antibodies in cardiac transplants. Am J Transplant. 2007;7:2605-2614.
38. Lachmann N, Todorova K, Schulze H, et al. Systematic comparison of four cell-and Luminex-based methods for assessment of complementactivating HLA antibodies. Transplantation. 2013;95:694-700.
39. Smith RN, Kawai T, Boskovic S, et al. Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant. 2008;8:1662-1672.
40. Lucas DP, Leffell MS, Zachary AA. Differences in immunogenicity of HLA antigens and the impact of cross-reactivity on the humoral response. Transplantation. 2015;99:77-85.
41. Kosmoliaptsis V, Gjorgjimajkoska O, Sharples LD, et al. Impact of donor mismatches at individual HLA-A,-B,-C,-DR, and-DQ loci on the development of HLA-specific antibodies in patients listed for repeat renal transplantation. Kidney Int. 2014;86:1039-1048.
42. Shoskes DA, Parfrey NA, Halloran PF. Increased major histocompatibility complex antigen expression in unilateral ischemic acute tubular necrosis in the mouse. Transplantation. 1990;49:201-207.
43. Hönger G, Krahenbuhl N, Dimeloe S, et al. Inter-individual differences in HLA expression can impact the CDC crossmatch. Tissue Antigens. 2015;85:260-266.
44. Petersdorf EW, Malkki M, O'HUigin C, et al. High HLA-DP expression and graft-versus-host disease. N Engl JMed. 2015;373:599-609.
45. Stanescu HC, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA (2)R1 alleles in idiopathic membranous nephropathy. NEngl JMed. 2011; 364:616-626.
46. Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl JMed. 2012;367:214-223.
47. Wahrmann M, Döhler B, Ruhenstroth A, et al. Genotypic diversity of complement component C4 does not predict kidney transplant outcome. J Am Soc Nephrol. 2011;22:367-376.
48. Bay JT, Schejbel L,MadsenHO, et al. Low C4 gene copy numbers are associated with superior graft survival in patients transplanted with a deceased donor kidney. Kidney Int. 2013;84:562-569.
49. Freedman BI, Julian BA, Pastan SO, et al. Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure. Am J Transplant. 2015;15:1615-1622.
50. Loupy A, Lefaucheur C, Vernerey D, et al. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol. 2014;25:2267-2277.
51. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation. 2009;87:1505-1513.
52. Regele H, Böhmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol. 2002;13:2371-2380.
53. Guidicelli G, Guerville F, Lepreux S, et al. Non-complement-binding de novo donor-specific anti-HLA antibodies and kidney allograft survival. J Am Soc Nephrol. 2016;27:615-625.